RTP Mobile Logo
Consensus or Controversy? Current and Future Management of Ovarian Cancer (Webinar Audio Proceedings)
Released November 2022

Featuring perspectives from Drs Ursula Matulonis and Debra Richardson. Published November 30, 2022. (Webinar Audio Proceedings)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of ovarian cancer.

    LEARNING OBJECTIVES

    • Consider available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer (OC), and counsel patients regarding personalized treatment recommendations.
    • Appreciate the biologic rationale for and published study data with PARP inhibitors in combination with other systemic therapies, and consider the implications of these findings for OC management and research.
    • Recognize the rationale for targeting folate receptor alpha and sodium-dependent phosphate transport protein 2b in OC, and consider available and emerging research findings with and the potential role of novel approaches to therapeutically exploit these biomarkers.
    • Describe the scientific rationale for the use of tumor treating fields (TTFs) in therapy for OC, and appraise the available efficacy and safety data with TTFs in combination with chemotherapy for patients with recurrent, advanced disease.
    • Compare and contrast the toxicities associated with PARP inhibitors and other novel agents under development for patients with OC, and offer supportive management strategies to minimize or ameliorate these side effects.
    • Recall the design of ongoing clinical trials evaluating novel agents and strategies for OC, and counsel appropriately selected patients about availability and participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Ursula Matulonis, MD
    Chief, Division of Gynecologic Oncology
    Brock-Wilson Family Chair
    Dana-Farber Cancer Institute
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: 2X Oncology, Agenus Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Clearity Foundation, ImmunoGen Inc, NextCure, Ovarian Cancer Research Alliance, Rivkin Foundation, Trillium Therapeutics Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, Novartis; Contracted Research: FUJIFILM Pharmaceuticals USA Inc, ImmunoGen Inc, Merck, Mersana Therapeutics Inc; Data and Safety Monitoring Board/Committee: Advaxis Inc, Alkermes, Symphogen A/S; Nonrelevant Financial Relationship: Med Learning Group.

    Debra L Richardson, MD
    Associate Professor
    Section Chief, Division of Gynecologic Oncology
    Stephenson Cancer Center
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Mersana Therapeutics Inc; Consulting Agreement: Mersana Therapeutics Inc; Contracted Research: Aravive Inc, Arch Oncology, Celsion Corporation, Clovis Oncology, GlaxoSmithKline, Harpoon Therapeutics, HOOKIPA Pharma Inc, Karyopharm Therapeutics, Mersana Therapeutics Inc, Roche Laboratories Inc, Shattuck Labs, Syros Pharmaceuticals Inc, Tesaro, A GSK Company; Steering Committee: Karyopharm Therapeutics (SIENDO trial), Tesaro, A GSK Company (OVARIO trial).

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    These activities are supported by educational grants from ImmunoGen Inc, Mersana Therapeutics Inc, and Novocure Inc.

    Release date: November 2022
    Expiration date: November 2023

Acknowledge and close

Watch video
(WIFI is recommended for best performance):